Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423683 · ClinicalTrials.gov registry record · Phase 3
Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
A Phase 3 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT00423683 is a Phase 3 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 64 participants.
The verdict
NCT00423683, a Phase 3 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare the two standard of care treatment options: anticoagulation with or without a inferior vena cava filter. The anticoagulation medication chosen will be Arixtra and it will be given once a day as an injection. Patients will be called at various intervals to monitor their signs and symptoms of new thromboembolisms.
Interventions
- DRUG Arixtra alone
- DEVICE Arixtra + filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423683
The ClinicalTrials.gov registry entry for NCT00423683 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arixtra alone is the first listed.
NCT00423683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423683 about?
NCT00423683 is a clinical study titled "Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism". The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare the two standard of care treatment options: anticoagula...
What is the current status of trial NCT00423683?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2007-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00423683?
The interventions under investigation include: Arixtra alone (DRUG), Arixtra + filter (DEVICE).
Who is sponsoring clinical trial NCT00423683?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.